Literature DB >> 12727273

Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants.

M J Jensen1, T J Smith, S A Ahmed, L A Smith.   

Abstract

Clostridial neurotoxins are potent inhibitors of synaptic function, with the zinc-dependent proteolytic light chain (LC) portion of the toxin cleaving one of three neural SNARE proteins. In nature, the LC is expressed as a part of a much larger toxin and hemagglutinin complex, protecting it from environmental degradation and preserving its catalytic activity. We developed forms of the LC of type A botulinum neurotoxin (BoNT-A) with parts of the larger toxin gene, for use as reagents in high-throughput assays to screen for potential LC antagonists, to further elucidate the toxin's mechanism of action, and to study immunological responses to the toxin. Three BoNT-A constructs were engineered and expressed: the LC, LC with translocation region (LC+H(n)), and the LC with the belt portion of the translocation region (LC+Belt). Purification was optimized to a two-step process, with relatively high yields of all three constructs obtained. Activity assays showed all three constructs to be active, with the LC being the most active. Immunogenic protection against native BoNT-A toxin challenge was observed for all three constructs, with the best protection observed with the LC+H(n) and LC+Belt proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727273     DOI: 10.1016/s0041-0101(03)00042-4

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  16 in total

1.  Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.

Authors:  Clifford Shone; Heidi Agostini; Joanna Clancy; Mili Gu; Huei-Hsiung Yang; Yanfang Chu; Virginia Johnson; Makie Taal; Joanna McGlashan; John Brehm; Xiaomi Tong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

2.  Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium.

Authors:  Rahman M Mizanur; John Gorbet; S Swaminathan; S Ashraf Ahmed
Journal:  Int J Biochem Mol Biol       Date:  2012-09-25

3.  Expression and purification of recombinant TAT-BoNT/A(1-448) under denaturing and native conditions.

Authors:  Parvaneh Saffarian; Shahin Najar Peerayeh; Jafar Amani; Firooz Ebrahimi; Hamid Sedighianrad; Raheleh Halabian; Abbas Ali Imani Fooladi
Journal:  Bioengineered       Date:  2016-08-26       Impact factor: 3.269

4.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.

Authors:  R Levy; C M Forsyth; S L LaPorte; I N Geren; L A Smith; J D Marks
Journal:  J Mol Biol       Date:  2006-10-03       Impact factor: 5.469

5.  High Yield Preparation of Functionally Active Catalytic-Translocation Domain Module of Botulinum Neurotoxin Type A That Exhibits Uniquely Different Enzyme Kinetics.

Authors:  Harkiranpreet Kaur Dhaliwal; Nagarajan Thiruvanakarasu; Raj Kumar; Kruti Patel; Ghuncha Ambrin; Shouwei Cai; Bal Ram Singh
Journal:  Protein J       Date:  2017-12       Impact factor: 2.371

6.  Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.

Authors:  Martha Hale; George Oyler; Subramanyam Swaminathan; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2010-10-20       Impact factor: 5.157

7.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

8.  The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Authors:  Rahman M Mizanur; Verna Frasca; Subramanyam Swaminathan; Sina Bavari; Robert Webb; Leonard A Smith; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

9.  Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.

Authors:  S Ashraf Ahmed; Mark A Olson; Matthew L Ludivico; Janice Gilsdorf; Leonard A Smith
Journal:  Protein J       Date:  2008-04       Impact factor: 2.371

10.  Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin.

Authors:  Tsuyoshi Takahashi; Suresh G Joshi; Fetweh Al-Saleem; Denise Ancharski; Ajay Singh; Zidoon Nasser; Lance L Simpson
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.